These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 25493593)
1. Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. Fabre-Mersseman V; Tubiana R; Papagno L; Bayard C; Briceno O; Fastenackels S; Dudoit Y; Rostane H; Salmon D; Costagliola D; Caby F; Sauce D; Viard JP; Appay V AIDS; 2014 Nov; 28(18):2677-82. PubMed ID: 25493593 [TBL] [Abstract][Full Text] [Related]
2. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846 [TBL] [Abstract][Full Text] [Related]
3. Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. Méndez-Lagares G; Pozo-Balado MM; Genebat M; García Pergañeda A; Leal M; Pacheco YM J Infect Dis; 2012 May; 205(10):1501-9. PubMed ID: 22457273 [TBL] [Abstract][Full Text] [Related]
4. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Eckard AR; O'Riordan MA; Rosebush JC; Lee ST; Habib JG; Ruff JH; Labbato D; Daniels JE; Uribe-Leitz M; Tangpricha V; Chahroudi A; McComsey GA Antivir Ther; 2018; 23(4):315-324. PubMed ID: 28994661 [TBL] [Abstract][Full Text] [Related]
6. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879 [TBL] [Abstract][Full Text] [Related]
7. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290 [TBL] [Abstract][Full Text] [Related]
8. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220 [TBL] [Abstract][Full Text] [Related]
9. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression. Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319 [TBL] [Abstract][Full Text] [Related]
10. Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment. Campillo-Gimenez L; Casulli S; Dudoit Y; Seang S; Carcelain G; Lambert-Niclot S; Appay V; Autran B; Tubiana R; Elbim C J Allergy Clin Immunol; 2014 Nov; 134(5):1142-52.e5. PubMed ID: 25042982 [TBL] [Abstract][Full Text] [Related]
11. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546 [TBL] [Abstract][Full Text] [Related]
12. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. Steel A; John L; Shamji MH; Henderson DC; Gotch FM; Gazzard BG; Kelleher P HIV Med; 2008 Feb; 9(2):118-25. PubMed ID: 18257774 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation. Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652 [TBL] [Abstract][Full Text] [Related]
14. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy. Stone SF; Price P; French MA HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533 [TBL] [Abstract][Full Text] [Related]
15. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688 [TBL] [Abstract][Full Text] [Related]
16. Persistent subclinical immune defects in HIV-1-infected children treated with antiretroviral therapy. van den Heuvel D; Driessen GJ; Berkowska MA; van der Burg M; Langerak AW; Zhao D; Charif H; Hartwig NG; van Rossum AM; Fraaij PL; van Dongen JJ; van Zelm MC AIDS; 2015 Sep; 29(14):1745-56. PubMed ID: 26372381 [TBL] [Abstract][Full Text] [Related]
17. CD38+CD8+ T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals. Kolber MA AIDS; 2008 Oct; 22(15):1937-41. PubMed ID: 18784457 [TBL] [Abstract][Full Text] [Related]
18. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C; J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199 [TBL] [Abstract][Full Text] [Related]
19. CD8 TCR β chain repertoire expansions and deletions are related with immunologic markers in HIV-1-infected patients during treatment interruption. González-Serna A; Abad-Fernández M; Soriano-Sarabia N; Leal M; Vallejo A J Clin Virol; 2013 Dec; 58(4):703-9. PubMed ID: 24210957 [TBL] [Abstract][Full Text] [Related]
20. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. Méndez-Lagares G; García-Pergañeda A; del Mar del Pozo-Balado M; Genebat M; Ruiz-Mateos E; García García M; Muñoz-Fernández MÁ; Pacheco YM; Leal M J Antimicrob Chemother; 2012 May; 67(5):1228-37. PubMed ID: 22287235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]